Skip to main content

Cardiff Oncology, Inc 8-K/A, filed Jun 17, 2020

Cardiff Oncology, Inc. (CRDF)

8-K/A 2020-06-17 For: 2020-06-15
View Original
Added on April 11, 2026

About this 8-K/A

Cardiff Oncology, Inc filed this 8-K/A on June 17, 2020, reporting on events of June 15, 2020.

Items reported

  • Item 8.01: Other events

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 15, 2020

cardifflogorgbtm11.jpg

Cardiff Oncology, Inc.

(Exact name of registrant as specified in its charter)

Delaware 001-35558 27-2004382
(State or other jurisdiction (Commission File Number) IRS Employer
of incorporation or organization) Identification No.)

11055 Flintkote Avenue

San Diego, CA 92121

(Address of principal executive offices)

Registrant’s telephone number, including area code: (858) 952-7570

Trovagene, Inc

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class: Trading Symbol(s) Name of each exchange on which registered:
Common Stock CRDF Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o             Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o             Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

EXPLANATORY NOTE

On June 16, 2020, Cardiff Oncology, Inc. (the “Company”) filed a current report on Form 8-K (the “Original Report”) to report the entry of a securities purchase agreement with certain institutional investors by the Company.

This current report on Form 8-K/A amends Item 8.01 – Other Events – to the Original Report, and describes the press release announcing such financing and should be read in conjunction with the Original Report. Except as stated above, no other information contained in the Original Report has been amended.

Item 8.01 Other Events.

On June 16, 2020, the Company issued a press release announcing it has entered into a securities purchase agreement, jointly led by biotech-focused fundamental institutional investors, Acorn Bioventures and CAM Capital, at the closing price as of June 15, 2020. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated:         June 16, 2020

CARDIFF ONCOLOGY, INC.
By: /s/ Mark Erlander
Mark Erlander
Chief Executive Officer

2